362 related articles for article (PubMed ID: 9848446)
1. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis.
Yang B; Koga H; Ohno H; Ogawa K; Fukuda M; Hirakata Y; Maesaki S; Tomono K; Tashiro T; Kohno S
J Antimicrob Chemother; 1998 Nov; 42(5):621-8. PubMed ID: 9848446
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Cavusoglu C; Karaca-Derici Y; Bilgic A
Clin Microbiol Infect; 2004 Jul; 10(7):662-5. PubMed ID: 15214882
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis.
Park YK; Kim BJ; Ryu S; Kook YH; Choe YK; Bai GH; Kim SJ
Int J Tuberc Lung Dis; 2002 Feb; 6(2):166-70. PubMed ID: 11931418
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of the antimycobacterial activities of rifabutin and the relationship between drug-resistance and rpoB mutations of Mycobacterium tuberculosis].
Han XQ; Huang HR; Li YJ; Yu X; Gao JT; Bi ZQ; Chu NH; Li L; Ma Y
Zhonghua Jie He He Hu Xi Za Zhi; 2011 Oct; 34(10):762-5. PubMed ID: 22321711
[TBL] [Abstract][Full Text] [Related]
5. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the
Guo Y; Cao X; Yang J; Wu X; Liu Y; Wan B; Hu L; Wang H; Yu F
J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33507146
[No Abstract] [Full Text] [Related]
6. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
Williams DL; Spring L; Collins L; Miller LP; Heifets LB; Gangadharam PR; Gillis TP
Antimicrob Agents Chemother; 1998 Jul; 42(7):1853-7. PubMed ID: 9661035
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.
Wichelhaus T; Schäfer V; Brade V; Böddinghaus B
J Antimicrob Chemother; 2001 Feb; 47(2):153-6. PubMed ID: 11157898
[TBL] [Abstract][Full Text] [Related]
8. Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.
Moghazeh SL; Pan X; Arain T; Stover CK; Musser JM; Kreiswirth BN
Antimicrob Agents Chemother; 1996 Nov; 40(11):2655-7. PubMed ID: 8913484
[TBL] [Abstract][Full Text] [Related]
9. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.
Berrada ZL; Lin SY; Rodwell TC; Nguyen D; Schecter GF; Pham L; Janda JM; Elmaraachli W; Catanzaro A; Desmond E
Diagn Microbiol Infect Dis; 2016 Jun; 85(2):177-81. PubMed ID: 27036978
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis].
Sato K; Tomioka H; Saito H; Kawahara S; Hidaka T
Kekkaku; 1996 Aug; 71(8):459-64. PubMed ID: 8831191
[TBL] [Abstract][Full Text] [Related]
11. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis.
Taniguchi H; Aramaki H; Nikaido Y; Mizuguchi Y; Nakamura M; Koga T; Yoshida S
FEMS Microbiol Lett; 1996 Oct; 144(1):103-8. PubMed ID: 8870258
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?
Schön T; Juréen P; Chryssanthou E; Giske CG; Kahlmeter G; Hoffner S; Angeby K
J Antimicrob Chemother; 2013 Sep; 68(9):2074-7. PubMed ID: 23633684
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of rifabutin resistance by a rifampicin resistant mutant of Mycobacterium tuberculosis involves an unusual spectrum of mutations and elevated frequency.
Anthony RM; Schuitema AR; Bergval IL; Brown TJ; Oskam L; Klatser PR
Ann Clin Microbiol Antimicrob; 2005 Jun; 4():9. PubMed ID: 15958167
[TBL] [Abstract][Full Text] [Related]
14. Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia.
Sintchenko V; Chew WK; Jelfs PJ; Gilbert GL
Pathology; 1999 Aug; 31(3):257-60. PubMed ID: 10503273
[TBL] [Abstract][Full Text] [Related]
15. [Genetic evaluation for rifampicin-susceptibility of Mycobacterium tuberculosis].
Ohno H; Koga H; Ogawa K; Sasaki E; Bing Y; Yanagihara K; Yamamoto Y; Maesaki S; Hirakata Y; Tomono K; Tashiro T; Kohno S
Kansenshogaku Zasshi; 1997 Apr; 71(4):323-8. PubMed ID: 9164087
[TBL] [Abstract][Full Text] [Related]
16. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.
Jamieson FB; Guthrie JL; Neemuchwala A; Lastovetska O; Melano RG; Mehaffy C
J Clin Microbiol; 2014 Jun; 52(6):2157-62. PubMed ID: 24740074
[TBL] [Abstract][Full Text] [Related]
17. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated in Brazil and France.
Spindola de Miranda S; Kritski A; Filliol I; Mabilat C; Panteix G; Drouet E
Mem Inst Oswaldo Cruz; 2001 Feb; 96(2):247-50. PubMed ID: 11285505
[TBL] [Abstract][Full Text] [Related]
18. Rifampicin and rifabutin resistance in 1003 Mycobacterium tuberculosis clinical isolates.
Farhat MR; Sixsmith J; Calderon R; Hicks ND; Fortune SM; Murray M
J Antimicrob Chemother; 2019 Jun; 74(6):1477-1483. PubMed ID: 30793747
[TBL] [Abstract][Full Text] [Related]
19. Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis.
Bodmer T; Zürcher G; Imboden P; Telenti A
J Antimicrob Chemother; 1995 Feb; 35(2):345-8. PubMed ID: 7759399
[No Abstract] [Full Text] [Related]
20. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations.
ElMaraachli W; Slater M; Berrada ZL; Lin SY; Catanzaro A; Desmond E; Rodrigues C; Victor TC; Crudu V; Gler MT; Rodwell TC
Int J Tuberc Lung Dis; 2015 Oct; 19(10):1222-6. PubMed ID: 26459537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
